mRNA latecomer CureVac recruits Bayer to speed COVID-19 vaccine to market
Compared with Moderna and the Pfizer-BioNTech partnership, which already have their COVID-19 vaccines authorized for emergency use, CureVac seems a little late to the mRNA...
CureVac
Targeted delivery, oral vaccines and mRNA 2.0: The next generation of drugs and prophylactics in the fight against COVID-19
As the chapter closes on the first year of the COVID-19 pandemic, drugmakers are hard at work bolstering the defenses mounted in 2020—and they’re looking at...
CureVac ties up Wacker to churn out more than 100M doses of mRNA coronavirus vaccine
Riding a wave of interest in mRNA-based vaccines, Germany’s CureVac is looking to rapidly drive manufacturing of its own shot candidate. After announcing a plan...
Moderna, EU clinch supply deal for 160M doses of mRNA-based coronavirus vaccine
With two leading mRNA-based COVID-19 vaccines racing toward approvals, nations are looking to secure enough doses to get the winning shot—or shots—into patients’ arms as...
CureVac, armed with COVID-19 vaccine deal, plots ‘pandemic-scale’ Euro manufacturing expansion
As Pfizer and Moderna dominate headlines with positive interim readouts for their COVID-19 vaccine candidates, other mRNA players are taking note. Germany’s CureVac, hot on the heels of...
CureVac, EU ink supply deal for up to 405M doses of mRNA coronavirus shot: Reuters
With mRNA-based coronavirus vaccines from Pfizer and Moderna showing promise in late-stage studies, another company working on a mid-stage mRNA candidate has inked a large supply deal with...
CureVac’s mRNA coronavirus shot boasts one advantage over Pfizer and Moderna counterparts—refrigerated storage
While Pfizer’s COVID-19 vaccine turned in strong early efficacy numbers and NIAID director Anthony Fauci said he expects similar figures from Moderna, the new class...
Pfizer-BioNTech COVID vaccine data ‘open the floodgates’ for mRNA in infectious disease. Other areas? Not so fast: analysts
The entire scientific community is cheering on Pfizer and BioNTech’s early COVID-19 vaccine data. Beyond the obvious boon for fighting the pandemic, the 90% efficacy...
Pfizer-BioNTech COVID vaccine data ‘open the floodgates’ for mRNA in infectious disease. Other areas? Not so fast: analysts
The entire scientific community is cheering on Pfizer and BioNTech’s early COVID-19 vaccine data. Beyond the obvious boon for fighting the pandemic, the 90% efficacy...
New global lab network will compare vaccines head-to-head
LONDON: A major non-profit health emergencies group has set up a global laboratory network to assess data from potential Covid-19 vaccines, allowing scientists and drugmakers...